Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Aegerion Pharmaceuticals, Inc. (AEGR): A $90 Price Target for This Biotech! How’s It Figured?

The first exception is with Regeneron Pharmaceuticals. It trades at 7.71 times EYLEA’s peak sales while Alexion trades at 5.15 times Soliris’ peak sales. The reason this is significant is because Soliris has higher sales potential. However, Regeneron also has a larger pipeline, including 12 in its pipeline, and a Phase 3 cholesterol drug called Alirocuma that could reach sales in excess of $3 billion annually. Thus, Soliris has more peak sales potential than EYLEA – but Regeneron has a more significant pipeline – as Alexion’s pipeline is built around additional indications of Soliris.

The second exception is with Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR). The company is the most expensive of all when comparing peak sales to targeted valuations. Yet, Juxtapid has the lowest peak sales potential of any drug that is charted. Sarepta Therapeutics’ drug Eteplirsen has almost three times the sales potential of Juxtapid and its targeted valuation is only a fraction compared to that of Aegerion. Therefore, it is hard to determine why Canaccord insisted on issuing such a bullish price target.

Final Thoughts

Personally, I think Aegerion is setting itself up for major post-launch losses. Right now the stock is trading higher on momentum, and investors are losing sight of the drug’s limited sales potential. While Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)management has raised Juxtapid’s price tag, I tend to lean more towards the FDA – and data that shows only 315 U.S. occurrences of homozygous familial hypercholesterolemia. Thus, I believe $250 million in revenue will be a tough feat for the company.

In biotechnology, sales compared to valuation is what ultimately creates value – and products that have larger sales potential warrant a more expensive valuation relative to sales. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) might in fact have a great product, and might in fact be a great company. However, we are not arguing these two points. We are discussing whether Aegerion’s price target of $90 is too expensive. Based on the comparisons that I have shown, there is little doubt that Canaccord’s $90 price target is way too excessive.

Brian Nichols is long SRPT. The Motley Fool has no position in any of the stocks mentioned.

The article A $90 Price Target for This Biotech! How’s It Figured? originally appeared on Fool.com.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.